TATA HEALTH (01255) Reports 2024 Interim Results with Shareholder Loss of HK$5.13 Million, Narrowed by 58.38% Year-over-Year

Stock News
09/22

TATA HEALTH (01255) announced its results for the six months ended June 30, 2024. The group recorded revenue of HK$72.309 million during the period, representing a decrease of 30.56% compared to the same period last year. The loss attributable to owners of the company was HK$5.13 million, which narrowed by 58.38% year-over-year. Basic loss per share was HK$0.02.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10